Lumida
/VNDA
⌘K
Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc

VNDA
$5.09USD+0.99%+0.05 today

MARKET CAP

298.5M

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$4
$10

AI Summary

Stalk
TrimMedium

VNDA remains in a sustained Stage 4 decline with a clear sequence of lower highs and lower lows and a primary Support Failure pattern. Volume expansion on down moves and declining EMAs confirm medium-term bearish permission, but extreme oversold readings and extended price below sloping EMAs argue against immediate selling. Under a Speculative mandate, we defer entry until a reaction rally into the falling 9/21 EMAs offers a disciplined shorting opportunity in the resistance zone.

  • EMA’s positive opinion for Imsidolimab in GPP orphan treatment marks key pipeline catalyst.
  • Renaissance increases stake by 11.2% in Q1, boosting institutional confidence.
  • Q2 EPS loss of $0.82 misses $0.69 consensus, signaling earnings risk.
Full analysis →

Buying

7

institutions

Selling

6

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

InstitutionActionShares HeldValueChangeChg %Weight
BI

Blackrock, Inc.

Q2 2026

BUY7.65 M46.84 M+377.75 K-6.8%0.00%
AC

Aqr Capital Management LLC

Q2 2026

BUY3.50 M21.41 M+1.89 M+93.2%0.01%
RT

Renaissance Technologies LLC

Q2 2026

SELL3.44 M21.06 M+-318.20 K-18.9%0.03%
MM

Millennium Management LLC

Q2 2026

SELL1.60 M9.81 M+-278.19 K-24.5%0.00%
CA

Citadel Advisors LLC

Q2 2026

BUY850.40 K5.20 M+25.15 K-8.7%0.00%
PA

Point72 Asset Management, L.P.

Q2 2026

BUY311.36 K1.91 M+149.77 K+70.7%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

SELL292.72 K1.80 M+-12.17 K-11.3%0.00%
MG

Man Group Plc

Q2 2026

BUY153.56 K939.77 K+73.50 K+69.9%0.00%
BA

Balyasny Asset Management L.P.

Q2 2026

SELL64.93 K397.35 K+-40.16 K-45.3%0.00%
GM

Grantham, Mayo, Van Otterloo & Co. LLC

Q2 2026

BUY28.34 K173.47 K+12.02 K+53.8%0.00%
BH

Brevan Howard Capital Management LP

Q2 2026

BUYNEW12.89 K78.87 K+12.89 K+0.0%0.00%
RC

Rockefeller Capital Management L.P.

Q2 2026

SELL472.002.89 K+-652.00-62.8%0.00%
WP

Woodline Partners LP

Q2 2026

SELL0.000.00+-415.33 K-100.0%0.00%